• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Disclosed herein are collagen films which rapidly dissolve at 35° C. Also disclosed are methods for the preparation of the collagen films and their use as a vehicle for delivering a dose of therapeutic compound to a specific tissue site.
    公开号:US20010001669A1
    申请号:US09/735,182
    申请日:2000-12-12
    公开日:2001-05-24
    发明作者:Dale DeVore；Richard Eiferman；Edwin Keates
    申请人:Devore Dale P.；Eiferman Richard A.；Keates Edwin U.；
    IPC主号:A61K9-7007
    专利说明:
    [0001] In general, the invention relates to rapidly dissolving collagen films, methods of preparation, and the use of these films for rapid compound delivery. [0001]
    [0002] The ability to specifically deliver a compound to a particular site in the human body is a desirable goal in many areas of medicine. For example, in cancer therapy, administration of chemotherapeutic agents to a tumor site with minimal exposure to surrounding tissues would dramatically reduce undesirable side effects to the surrounding tissues, or the body as a whole, while facilitating delivery of potent doses to malignant cells. [0002]
    [0003] In addition, the inhibition of wound healing is beneficial in certain circumstances, for example, following glaucoma filtration surgery (otherwise known as trabeculectomy). The initial stage in the process of wound healing is characterized by the movement of intravascular components, such as plasma and blood proteins, to the extravascular area (Peacock, In: Wound Repair, 491-492, 1984, ed. EE Peacock, WB Saunders Co, Philadelphia, Pa.). Neutrophils and macrophages then migrate to the injury site, functioning to prevent infection and promote fibroblast migration. Subsequent phases of wound healing include fibroblast secretion of collagen, collagen stabilization, angiogenesis, and wound closure (Costa et al., Opth. Surgery 24: 152-170, 1993). [0003]
    [0004] During surgery for the treatment of glaucoma, a fistula is frequently created to allow for post-operative drainage of intraopthalmic fluid from the eye. Accordingly, the inhibition of fistula healing is beneficial in order to extend the drainage time and reduce intraopthalmic pressure. Several therapies have been adopted to inhibit fistula healing, including beta irradiation, 5-fluorouracil treatment, and mitomycin (also known as mitomycin-C or mitomicin) treatment (Costa et al., Opth. Surgery 24: 152-170, 1993). [0004] SUMMARY OF THE INVENTION
    [0005] The present invention provides a method of preparing a rapidly dissolving collagen film which includes a therapeutic compound. The method involves (i) preparing a purified solution of monoreactive-amine modified collagen, e.g., a glutaric anhydride derivatized collagen, (ii) heating the collagen solution to about 35-45° C. for a time sufficient to reduce collagen viscosity, (iii) adding the compound to the heated collagen solution, and iv) casting the solution into thin layers, wherein the solution dries and forms the film. [0005]
    [0006] The invention also includes a collagen film prepared by the above described method and a collagen film which rapidly dissolves upon exposure to about 35° C. Preferably, the collagen film dissolves within five to ten minutes upon exposure to about 35° C. More preferably, the collagen film dissolves within two minutes upon exposure to about 35° C. . Most preferably, the collagen film dissolves within one minute or 30 seconds upon exposure to about 35° C. [0006]
    [0007] The therapeutic compound contained within the rapidly dissolving collagen film may be an inhibitor of cell proliferation, e.g., an anti-metabolic antibiotic, anti-metabolite, anti-fibrotic, anti-viral compound, or angiostatic compound. Preferably, the compound is an anti-metabolic antibiotic, e.g., mitomycin, daunorubicin, mithramycin, bleomycin, or doxorubicin. [0007]
    [0008] Alternatively, the therapeutic compound may be an anti-metabolite. Examples of useful anti-metabolites include 5-fluorouracil, 5-fluorouridine-5′-monophosphate, 5-fluorodeoxyuridine, 5-fluorodeoxyuridine-5′-monophosphate, and 5-fluroorotate. [0008]
    [0009] In yet other applications, the therapeutic compound contained within the rapidly dissolving collagen film is an anti-fibrotic. Examples of useful anti-fibrotics include inhibitors of prolyl nydroxylase and lysyl hydroxylase, e.g., iron chelators, α,α-dipyridyl, o-phenanthroline, proline analogs, lysine analogs, and free radical inhibitors and scavengers; inhibitors of collagen secretion, e.g., colchicine, vinblastin, cytochalasin B, copper, zinc, and EGTA; inhibitors of collagen secretion and maturation, e.g., BAPN, vincristine, and D-penicillamine; and stimulators of collagen degradation, e.g., EDTA and colchicine. [0009]
    [0010] As noted above, the therapeutic compound may also be an anti-viral drug. Examples of anti-viral drugs that can be used in the invention include vidarabine, acyclovir, AZT, and amantadine. [0010]
    [0011] Finally, angiostatic drugs, e.g., angiostatin, as well as other miscellaneous anti-cell proliferative drugs, e.g., tissue plasminogen activator (TPA), heparin, cytosine arabinoside, and gamma-interferon, may also be used in the rapidly dissolving collagen films described herein. [0011]
    [0012] In addition to methods of collagen film preparation, the invention also provides a method of rapidly delivering a compound dose to a specific tissue site in a mammal. The method involves administering a collagen film containing the compound dose to the tissue site, wherein the collagen film rapidly dissolves upon exposure to the mammalian tissue site. Using this method to deliver toxic compounds, the toxic side effects are essentially restricted to the specific tissue site of compound delivery. [0012]
    [0013] In a related aspect, the invention also includes a method of treating a mammal to inhibit cellular proliferation, e.g., wound healing or tumor growth, at a specific tissue site. The method involves administering a collagen film comprising an inhibitor of cell proliferation, e.g., an anti-metabolic antibiotic, anti-metabolite, anti-fibrotic, anti-viral compound, or angiostatic compound, to the tissue site, wherein the collagen film rapidly dissolves upon exposure to the tissue and delivers a dose of the compound sufficient to inhibit cell proliferation at the tissue site. [0013]
    [0014] In preferred embodiments, the cell proliferation inhibitor is mitomycin, 5-fluorouracil, or an anti-fibrotic. In addition, in other preferred embodiments, the collagen film dissolves within five to ten minutes upon exposure to the mammalian tissue site, more preferably, within two minutes, and, most preferably, within one minute or 30 seconds. In addition, the mammal is preferably a human. [0014]
    [0015] This method can be used, for example, in treating a mammal undergoing surgery for glaucoma. In this application, the collagen film is administered to the trabeculectomy-created fistula in the mammal, wherein the dose of cell proliferation inhibitor is sufficient to inhibit closure of the fistula. Preferably, the cell proliferation inhibitor used is mitomycin at a dose of 200-400 μg and may be administered in a 4×4 mm collagen film patch. Most preferably, the mitomycin dose is 400 μg. [0015]
    [0016] Use of this treatment results in reduced post-operative intraocular pressure. Preferably, post-operative intraocular pressure as a result of this method is less than 16 mmHg, more preferably, less than 12 mmHg, and, most preferably, less than 6 mmHg. [0016]
    [0017] As used herein, by “mono-reactive amine-modified” is meant reacted with a monoreactive amine-modifying agent, also known as a monoacylating or sulfonating agent. Useful agents include, without limitation, anhydrides, acid halides, sulfonyl halides, and active esters. The modifying agent is preferably a compound or combination of compounds which contains an acidic, carboxylic, or sulfonide group, or generates an acidic, carboxylic, or sulfonic group during reaction. [0017]
    [0018] By “inhibitor of cell proliferation” is meant an inhibitor of an increase in the number of cells located at a particular site. Such inhibition may occur by inhibition of cell migration or attachment, cell replication, cell survival, or angiogenesis. [0018]
    [0019] By “specific tissue site” is meant the area of tissue directly in contact with the collagen film administered to the tissue. [0019]
    [0020] By “rapidly dissolves” is meant dissolves, or melts, in approximately 30 minutes or less. [0020]
    [0021] The present invention provides a number of advantages. For example, the present techniques and collagen film compositions facilitate an improved approach for delivering a compound in situations where both a precise dose and accurate placement are required. The dose can be adjusted to any desired amount, i.e., by modifying the concentration of compound in the film or the size of the film, and the solid nature of the film allows its placement at any site in the body which can be reached by surgical techniques. In addition, the invention provides for the rapid dissolution of the collagen film upon exposure to normal body temperature. Taken together, these features ensure that a delivered compound achieves a certain concentration at a specific site, reducing possible inaccuracy due to mistaken dose or improper placement. [0021]
    [0022] For delivery of mitomycin or 5-fluorouracil to a post-trabeculectomy fistula, the present invention represents an improvement over current empirical techniques employed, which typically involve placing a sponge wetted with compound on the fistula site for 3-5 minutes. [0022]
    [0023] The advantage of delivering essentially all compound to a specific site also provides for limited compound delivery to tissues surrounding the delivery site. This advantage is especially relevant when the compound to be delivered has toxic effects. By restricting delivery to the targeted tissues, any unintentional or unnecessary toxic damage to surrounding tissues is reduced. [0023]
    [0024] Furthermore, compounds, such as mitomycin, exhibit increased stability in the collagen film as compared to stability in solution. Thus, one collagen film sample preparation can be subdivided and used for several applications over the course of several weeks. This feature provides the advantages of reducing experimental variation when administered over several days and eliminating the need for daily pre-surgical sample preparation. [0024]
    [0025] Other features and advantages of the invention will be apparent from the following detailed description thereof, and from the claims. [0025] DETAILED DESCRIPTION OF THE INVENTION
    [0026] Described herein are methods of preparing collagen films containing therapeutic compounds that readily dissolve upon exposure to normal human body temperature (35-37° C.). These collagen films can be used for the rapid and accurate delivery of compounds to specific tissue sites. [0026]
    [0027] For the purposes of this invention, collagen can be collected, solubilized, subjected to modification by mono-reactive, amine-modifying agents, and re-precipitated by any standard technique, e.g., those provided in DeVore et al. (U.S. Pat. No. 4,713,446), herein incorporated by reference. The following example is provided as an illustration and is in no way intended to limit the scope of the invention. [0027]
    [0028] Preparation of Collagen [0028]
    [0029] As a first step toward producing rapidly dissolving films, soluble collagen was prepared by standard procedures. Young calf hide was washed thoroughly with reagent alcohol and with deionized, pyrogen-free water, cut into approximately 1 cm[0029] 2 sections, and stirred overnight in 40 volumes of 0.5 M acetic acid. The mixture was then supplemented with pepsin (3% hide wet weight) and stirred for 72 hours. The digested, solubilized collagen was filtered through cheesecloth and precipitated by increasing the NaCl concentration to 0.8 M. The collagen was then cycled twice through steps of redissolution, in 0.5 M acetic acid, and reprecipitated. The collagen precipitate was then redissolved in 0.1 N acetic acid, dialyzed against 0.1 M acetic acid, filtered (0.45 μm), and refiltered (0.22 μm).
    [0030] The purified, telopeptide-poor collagen was derivatized with glutaric anhydride as previously described (U.S. Pat. Nos. 5,631,243 and 5,492,135). Briefly, the collagen solution (approximately 3 mg/ml) was adjusted to pH 9.0 with 10 N and 1 N NaOH. While stirring the solution, glutaric anhydride was added at 10% (weight of collagen). For twenty minutes, the stirring continued, and the pH was maintained. [0030]
    [0031] The pH of the solution was adjusted to 4.3 with 6 N and 1 N HCl to precipitate the derivatized collagen. The precipitate was centrifuged at 3500 rpm for 30 minutes. The pellet was washed three times in pyrogen-free deionized water and then redissolved in phosphate buffered glycerol (2% glycerol in 0.004 M phosphate buffer, pH 7.4) to achieve a final concentration of approximately 10 mg/ml. [0031]
    [0032] Preparation of Collagen Films Containing Mitomycin [0032]
    [0033] To prepare collagen films containing mitomycin, the collagen solution, described above, was heated in a 35° C. water bath for 30 minutes to reduce viscosity. Mitomycin (e.g., Mutamycin®, Bristol Myers Squibb, Princeton, N.J.), also known as mitomicin C, was added to the heated collagen. The collagen solution was then poured into petri dishes in a thin layer and allowed to air dry under a laminar-flow hood. [0033]
    [0034] Collagen film melting time at 35° C. was measured after placing the films in 0.8% saline in a 35° C. water bath. Pre-heated collagen films melted in approximately one minute. In contrast, collagen films poured into petri dishes without pre-heating melted at 35° C. in approximately 30 minutes. [0034]
    [0035] Mitomycin-containing collagen films had a final mitomycin concentration of 400 μg per 16 mm[0035] 2. 6 mm diameter discs were cut from the film and applied to human subconjunctival fibroblasts derived from Tenon's membrane layered in 96 well plates (CSM supplemented with 10% fetal bovine serum). After 72 hours, mitomycin-induced inhibition of cell division was assessed by measuring the reduction in fluorescence intensity (RFU) using a fluorogenic CalceinAM assay (see, for example, Decherchi et al., J. Neurosci. Meth. 71: 205 (1997); Sugita, Pflitgers Arch. 429: 555 (1995); Padanilam et al., Ann. NY Acad. Sci. 720: 111 (1994); Lichtenfels et al., J. Immunol. Meth. 172: 227 (1994); and Wang et al., Human Immunol. 37: 264 (1993)). The mitomycin-containing collagen films inhibited approximately 91% of the cell division demonstrated in control cells.
    [0036] Mitomycin-containing films may be stored for later use. For example, mitomycin activity in the collagen films described above was maintained for at least 6 weeks after preparation of the films (stored at 4° C.). Administration of mitomycin-collagen films, 2, 4, and 6 weeks old, demonstrated 91%, 90%, and 92% inhibition of cell division, respectively, compared to mitomycin-free controls. These values were comparable to the % cell death inhibition elicited by administration of a freshly prepared mitomycin solution (0.4 mg/ml solution, dissolved in USP sterile water). [0036]
    [0037] In contrast to the stability of mitomycin in the collagen film, HPLC analysis of the mitomycin solution determined that stability was maintained for only 4 days following storage at ambient temperature and 4° C. in the dark. Dissolution and storage in 0.9% saline or phosphate buffer (pH 7.4) is not recommended due to degradation and precipitation. [0037]
    [0038] Use [0038]
    [0039] Rapidly dissolving collagen films containing therapeutic compounds are useful for various treatments. For example, the collagen-mitomycin film may be administered to the external opening of the fistula created during glaucoma filtering surgery (trabeculectomy). Immediately following surgery, a collagen film, e.g., a 4×4 mm patch, containing 100-1000 μg mitomycin (preferably 400 μg), is directly applied to the external opening of the fistula prior to replacing the scleral flap. Administration of the mitomycin increases the duration of fistula patency, increasing filtration from the eye and reducing intraocular pressure. [0039]
    [0040] Other compounds may also be administered to the trabeculectomy-created fistula to increase filtration during recovery. For example, 5-fluorouracil-containing films may be administered in the same fashion to deliver a 5-fluorouracil dose of 25-250 μg (preferably 100 μg). Other alternative compounds that are effective for this treatment are anti-fibrotic, angiostatic, and anti-viral compounds. [0040]
    [0041] Administration of the rapidly dissolving collagen films containing inhibitors of cell proliferation are also useful for treatment during recovery from other surgical procedures where prevention of wound healing is beneficial. [0041]
    [0042] In addition, the collagen films of the invention may be administered to reduce cellular proliferation in specific tissue sites, such as for the localized inhibition of neoplastic or non-neoplastic cell growth. For this application, any chemotherapeutic compound may be dissolved in the collagen matrix in concentrations appropriate for inhibiting cell growth. [0042] OTHER EMBODIMENTS
    [0043] While the treatment regimens described herein are preferably applied to human patients, they also find use in the treatment of other animals, such as domestic pets or livestock. [0043]
    [0044] Moreover, while the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the appended claims. [0044]
    权利要求:
    Claims (15)
    [1" id="US-20010001669-A1-CLM-00001] 1. A method of preparing a rapidly dissolving collagen film which includes a therapeutic compound, said method comprising:
    a) preparing a purified solution of monoreactive-amine modified collagen;
    b) heating said collagen solution to about 35-45° C. for a time sufficient to reduce collagen viscosity;
    c) adding said compound to the heated collagen solution; and
    d) casting said solution into thin layers, wherein said solution dries and forms said film.
    [2" id="US-20010001669-A1-CLM-00002] 2. The method of
    claim 1 , wherein said collagen is modified by glutaric anhydride derivatization.
    [3" id="US-20010001669-A1-CLM-00003] 3. A collagen film prepared by the method of
    claim 1 .
    [4" id="US-20010001669-A1-CLM-00004] 4. A collagen film, wherein said film rapidly dissolves upon exposure to about 35° C.
    [5" id="US-20010001669-A1-CLM-00005] 5. The collagen film of
    claim 4 , wherein said collagen film dissolves within ten minutes upon exposure to about 35° C.
    [6" id="US-20010001669-A1-CLM-00006] 6. The collagen film of
    claim 4 , wherein said collagen film dissolves within five minutes upon exposure to about 35° C.
    [7" id="US-20010001669-A1-CLM-00007] 7. The collagen film of
    claim 4 , wherein said collagen film dissolves within two minutes upon exposure to about 35° C.
    [8" id="US-20010001669-A1-CLM-00008] 8. The collagen film of
    claim 4 , wherein said collagen film dissolves within one minute upon exposure to about 35° C.
    [9" id="US-20010001669-A1-CLM-00009] 9. The collagen film of
    claim 4 , wherein said collagen film dissolves within thirty seconds upon exposure to about 35° C.
    [10" id="US-20010001669-A1-CLM-00010] 10. The collagen film of
    claim 4 , wherein said film includes a compound which is an inhibitor of cell proliferation.
    [11" id="US-20010001669-A1-CLM-00011] 11. The collagen film of
    claim 10 , wherein said compound is an anti-metabolic antibiotic.
    [12" id="US-20010001669-A1-CLM-00012] 12. The collagen film of
    claim 11 , wherein said compound is mitomycin.
    [13" id="US-20010001669-A1-CLM-00013] 13. The collagen film of
    claim 4 , wherein said film includes a compound which is an anti-metabolite.
    [14" id="US-20010001669-A1-CLM-00014] 14. The collagen film of
    claim 13 , wherein said compound is 5-fluorouracil.
    [15" id="US-20010001669-A1-CLM-00015] 15. The collagen film of
    claim 4 , wherein said film includes a compound which is an anti-fibrotic.
    类似技术:
    公开号 | 公开日 | 专利标题
    US6448378B2|2002-09-10|Compound delivery using rapidly dissolving collagen film
    EP1797053B1|2010-11-03|Phenothiazinium compound for wound healing
    US6063396A|2000-05-16|Methods and compositions for the modulation of cell proliferation and wound healing
    US5618553A|1997-04-08|Methods and compositions for the modulation of cell proliferation and wound healing
    JP3145409B2|2001-03-12|Reduction of adhesions using controlled delivery of active oxygen inhibitors
    JP2007500548A|2007-01-18|Osmium compounds for reducing harmful inflammation
    JP2011503162A|2011-01-27|Solid composition
    EP0564722A1|1993-10-13|Lathyrogenic agents and apparatus for the treatment of fibrotic lesions
    US20080153795A1|2008-06-26|Medicaments and methods for wound healing
    JP2010519183A|2010-06-03|Polymerization using protein precipitation for elution of physiological solutions
    McGuigan et al.1987|D-penicillamine and beta-aminopropionitrile effects on experimental filtering surgery.
    AU2003222668A1|2003-11-10|Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
    KR20070080823A|2007-08-13|Hydrogel formulations comprising active drugs for treating wounds
    CA1112573A|1981-11-17|Solution of tranexamic acid
    RU2207852C2|2003-07-10|Agents for prophylaxis or treatment of diseases associated with abnormal proliferation of retina epithelial pigment cells
    WO2016176579A1|2016-11-03|Injectable sustained release intraocular device
    JP6863973B2|2021-04-21|Taurolidine skin penetration formulation
    CA2394471C|2010-05-25|External preparation for treating pruritus
    Haslinda et al.2015|Cyanoacrylate tissue glue for wound repair in early posttrabeculectomy conjunctival bleb leak: a case series
    US5002956A|1991-03-26|Use of heterocyclic compounds for iontophoretic treatment
    JPH0789859A|1995-04-04|Pharmaceutic composition containing pyrazine derivative and curing method for inhibiting neogenesis of new blood vessel
    Lee et al.2007|Slow-releasing tranilast in polytetrafluoroethylene/polylactide-co-glycolide laminate delays adjustment after strabismus surgery in rabbit model
    Romano et al.2011|The use of topical hyaluronic acid and silver sulfadiazine | in patients undergoing two-stage anterior urethroplasty with oral mucosal graft
    JPH07277981A|1995-10-24|Sustained release antineoplastic pharmaceutical preparation
    RU2495651C1|2013-10-20|Method of eye treating burns
    同族专利:
    公开号 | 公开日
    EP1079850A1|2001-03-07|
    EP1079850A4|2002-03-13|
    WO1999061047A1|1999-12-02|
    JP2002516289A|2002-06-04|
    US6197934B1|2001-03-06|
    US6448378B2|2002-09-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US20050287682A1|2004-06-28|2005-12-29|Lizzi Michael J|Dissolvable films and methods including the same|
    US10155080B2|2003-11-05|2018-12-18|Baxter International Inc.|Renal therapy system with cassette-based blood and dialysate pumping|JPS5325006B2|1973-08-17|1978-07-24|||
    US4164559A|1977-09-21|1979-08-14|Cornell Research Foundation, Inc.|Collagen drug delivery device|
    US4713446A|1985-09-06|1987-12-15|Minnesota Mining And Manufacturing Company|Viscoelastic collagen solution for ophthalmic use and method of preparation|
    US5660692A|1988-02-24|1997-08-26|Cedars-Sinai Medical Center|Method of crosslinking amino acid-containing polymers using photoactivatable chemical crosslinkers|
    US5219576A|1988-06-30|1993-06-15|Collagen Corporation|Collagen wound healing matrices and process for their production|
    US5162430A|1988-11-21|1992-11-10|Collagen Corporation|Collagen-polymer conjugates|
    JP3224815B2|1990-07-03|2001-11-05|コラゲネシスインコーポレイテッド|Viscoelastic solution based on collagen for visco-surgery|
    IL105529D0|1992-05-01|1993-08-18|Amgen Inc|Collagen-containing sponges as drug delivery for proteins|
    US5492135A|1992-09-09|1996-02-20|Devore; Dale P.|Collagen modulators for use in photoablation excimer laser keratectomy|
    CA2130295A1|1993-08-26|1995-02-27|Richard A. Berg|Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery|
    CA2140053C|1994-02-09|2000-04-04|Joel S. Rosenblatt|Collagen-based injectable drug delivery system and its use|WO2000052516A2|1999-03-01|2000-09-08|Boston Innovative Optics, Inc.|System and method for increasing the depth of focus of the human eye|
    US7045600B2|1999-11-29|2006-05-16|Nederlandse Organisatie Voor Toegepastnatuur-Wetenschappelijk Ondrezoek Tno|Modification of collagenous materials and medical treatment, diagnosis and monitoring of fibrotic conditions|
    US6939364B1|2001-10-09|2005-09-06|Tissue Adhesive Technologies, Inc.|Composite tissue adhesive|
    US6875427B1|2001-10-09|2005-04-05|Tissue Adhesive Technologies, Inc.|Light energized tissue adhesive|
    US6780840B1|2001-10-09|2004-08-24|Tissue Adhesive Technologies, Inc.|Method for making a light energized tissue adhesive|
    US6773699B1|2001-10-09|2004-08-10|Tissue Adhesive Technologies, Inc.|Light energized tissue adhesive conformal patch|
    TWI329105B|2002-02-01|2010-08-21|Rigel Pharmaceuticals Inc|2,4-pyrimidinediamine compounds and their uses|
    US6969525B2|2002-06-08|2005-11-29|James C. Y. Chow|Surgically implanted time release medication for post-surgical treatment of a patient|
    EP2316459B1|2002-07-29|2013-11-06|Rigel Pharmaceuticals, Inc.|2,4-pyrimidinediamine compounds for use in methods of treating or preventing autoimmune diseases|
    US20060172972A1|2002-12-20|2006-08-03|Chakshu Research Inc|Formulation and method for administration of ophthalmologically active agents|
    WO2004058289A1|2002-12-20|2004-07-15|Chakshu Research, Inc.|Ophthalmic formulation for the prevention and treatment of ocular conditions|
    US20060166879A1|2002-12-20|2006-07-27|Chakshu Research Inc|Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders|
    US20060177430A1|2002-12-20|2006-08-10|Chakshu Research Inc|Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer|
    US7628810B2|2003-05-28|2009-12-08|Acufocus, Inc.|Mask configured to maintain nutrient transport without producing visible diffraction patterns|
    US20050046794A1|2003-06-17|2005-03-03|Silvestrini Thomas A.|Method and apparatus for aligning a mask with the visual axis of an eye|
    AT506953T|2003-08-07|2011-05-15|Rigel Pharmaceuticals Inc|2,4-PYRIMIDINDIAMIN COMPOUNDS AND USES AS ANTIPROLIFERATIVE AGENTS|
    US20050136112A1|2003-12-19|2005-06-23|Pediamed Pharmaceuticals, Inc.|Oral medicament delivery system|
    WO2006024491A1|2004-08-30|2006-03-09|Interstitial Therapeutics|Methods and compositions for the treatment of cell proliferation|
    US8043609B2|2004-10-08|2011-10-25|Potentia Pharmaceuticals, Inc.|Viral complement control proteins for eye disorders|
    WO2006042252A2|2004-10-08|2006-04-20|Potentia Pharmeceuticals, Inc.|Viral complement control proteins for eye disorders|
    US7976577B2|2005-04-14|2011-07-12|Acufocus, Inc.|Corneal optic formed of degradation resistant polymer|
    EA200800338A1|2005-07-15|2008-08-29|Чакшу Рисерч Инк.|PREVENTION AND TREATMENT OF OPHTHALMOLOGICAL COMPLICATIONS OF DIABETES|
    CA2518298A1|2005-09-06|2007-03-06|Chaimed Technologies Inc.|Biodegradable polymers, their preparation and their use for the manufacture of bandages|
    US8168584B2|2005-10-08|2012-05-01|Potentia Pharmaceuticals, Inc.|Methods of treating age-related macular degeneration by compstatin and analogs thereof|
    PL1951279T3|2005-10-08|2017-12-29|Apellis Pharmaceuticals, Inc.|Compstatin and analogs thereof for eye disorders|
    US8962643B2|2006-02-24|2015-02-24|Rigel Pharmaceuticals, Inc.|Compositions and methods for inhibition of the JAK pathway|
    US9539241B2|2006-07-12|2017-01-10|Mobius Therapeutics, Llc|Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application|
    AT540041T|2006-11-21|2012-01-15|Rigel Pharmaceuticals Inc|PRODRUG SALTS OF 2,4-PYRIMIDINIAMIN COMPOUNDS AND APPLICATIONS THEREOF|
    US8580735B2|2007-02-05|2013-11-12|Apellis Pharmaceuticals, Inc.|Local complement inhibition for treatment of complement-mediated disorders|
    US20090004455A1|2007-06-27|2009-01-01|Philippe Gravagna|Reinforced composite implant|
    US20110092446A1|2007-07-20|2011-04-21|Cedric Francois|Compositions and methods for treatment of trauma|
    US9308068B2|2007-12-03|2016-04-12|Sofradim Production|Implant for parastomal hernia|
    JP2011517313A|2007-12-11|2011-06-02|ビアメトファーマシューティカルズ，インク．|Metalloenzyme inhibitors that use a metal binding moiety in combination with a targeting moiety|
    WO2009121065A2|2008-03-28|2009-10-01|Apellis Ag|Modulation and repletion/enhancement of the complement system for treatment of trauma|
    WO2009156866A2|2008-06-27|2009-12-30|Sofradim Production|Biosynthetic implant for soft tissue repair|
    JP5815411B2|2008-12-30|2015-11-17|ライジェル ファーマシューティカルズ， インコーポレイテッド|Pyrimidinediamine kinase inhibitor|
    EP2389372B1|2009-01-23|2015-09-09|Rigel Pharmaceuticals, Inc.|Compositions and methods for inhibition of the jak pathway|
    WO2010091198A1|2009-02-06|2010-08-12|University Of Southern California|Therapeutic compositions comprising monoterpenes|
    CN106420756A|2009-07-28|2017-02-22|里格尔药品股份有限公司|Compositions and methods for inhibition of the JAK pathway|
    JP5607163B2|2009-08-13|2014-10-15|アキュフォーカス・インコーポレーテッド|Intraocular implant and lens with mask|
    FR2949688B1|2009-09-04|2012-08-24|Sofradim Production|FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER|
    USD656526S1|2009-11-10|2012-03-27|Acufocus, Inc.|Ocular mask|
    WO2011109635A1|2010-03-03|2011-09-09|Neonc Technologies Inc.|Pharmaceutical compositions comprising monoterpenes|
    EA024341B1|2010-04-24|2016-09-30|Ваймет Фармасьютикалс, Инк.|Metalloenzyme inhibitor compounds|
    US9421240B2|2010-06-22|2016-08-23|Apellis Pharmaceuticals, Inc.|Compstatin analogs for treatment of neuropathic pain|
    CN103201280B|2010-07-28|2016-08-10|里格尔药品股份有限公司|The compositions of suppression JAK approach and method|
    WO2012027693A2|2010-08-27|2012-03-01|Neonc Technologies Inc.|Pharmaceutical compositions comprising poh derivatives|
    US20160038600A1|2012-08-03|2016-02-11|Neonc Technologies Inc.|Pharmaceutical compositions comprising poh derivatives|
    CA2816088A1|2010-10-28|2012-05-03|Viamet Pharmaceuticals, Inc.|Metalloenzyme inhibitor compounds|
    EP2638021B1|2010-11-13|2018-09-26|Innocrin Pharmaceuticals, Inc.|1-naphthalen-2-yl)-2-methyl-1-propan-1-ol as inhibitor of CYP17 for the treatment of androgen dependent diseases like prostate cancer|
    JP6122564B2|2010-12-17|2017-04-26|ネオンク テクノロジーズ インク．|Method and apparatus for using isoperyl alcohol|
    CA2828360A1|2011-02-25|2012-08-30|The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services|Chrysophaentin analogs that inhibit ftsz protein|
    FR2972626B1|2011-03-16|2014-04-11|Sofradim Production|PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED|
    EP3682896A1|2011-04-28|2020-07-22|University of Southern California|Human myeloid derived suppressor cell cancer markers|
    US8901121B2|2011-06-19|2014-12-02|Viamet Pharmaceuticals, Inc.|Metalloenzyme inhibitor compounds|
    KR20180095108A|2011-06-19|2018-08-24|비아멧 파마슈티컬즈, 인코포레이티드|Metalloenzyme inhibitor compounds|
    US8883797B2|2011-06-23|2014-11-11|Viamet Pharmaceuticals, Inc.|Metalloenzyme inhibitor compounds|
    FR2977789B1|2011-07-13|2013-07-19|Sofradim Production|PROSTHETIC FOR UMBILIC HERNIA|
    FR2977790B1|2011-07-13|2013-07-19|Sofradim Production|PROSTHETIC FOR UMBILIC HERNIA|
    CN103781499B|2011-09-30|2016-09-28|索弗拉狄姆产品公司|The reversible hardening of lightweight net|
    WO2013082545A1|2011-12-02|2013-06-06|Acufocus, Inc.|Ocular mask having selective spectral transmission|
    DK2788343T3|2011-12-11|2018-06-14|Viamet Pharmaceuticals Nc Inc|METALLOENZYMIN INHIBITOR COMPOUNDS|
    FR2985170B1|2011-12-29|2014-01-24|Sofradim Production|PROSTHESIS FOR INGUINAL HERNIA|
    FR2985271B1|2011-12-29|2014-01-24|Sofradim Production|KNITTED PICOTS|
    JP6189865B2|2012-01-20|2017-08-30|ヴィアメット ファーマスーティカルズ，インコーポレイテッド|Metalloenzyme inhibitor compounds|
    AU2013235729B2|2012-03-23|2017-06-01|Baylor University|Compositions and methods for inhibition of cathepsins|
    WO2013173506A2|2012-05-16|2013-11-21|Rigel Pharmaceuticals, Inc.|Method of treating muscular degradation|
    FR2994185B1|2012-08-02|2015-07-31|Sofradim Production|PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER|
    FR2995778B1|2012-09-25|2015-06-26|Sofradim Production|ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME|
    FR2995779B1|2012-09-25|2015-09-25|Sofradim Production|PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION|
    FR2995788B1|2012-09-25|2014-09-26|Sofradim Production|HEMOSTATIC PATCH AND PREPARATION METHOD|
    US10159555B2|2012-09-28|2018-12-25|Sofradim Production|Packaging for a hernia repair device|
    US10035822B2|2012-11-15|2018-07-31|Apellis Pharmaceuticals, Inc.|Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods|
    US9204962B2|2013-03-13|2015-12-08|Acufocus, Inc.|In situ adjustable optical mask|
    US9427922B2|2013-03-14|2016-08-30|Acufocus, Inc.|Process for manufacturing an intraocular lens with an embedded mask|
    US10308687B2|2013-03-15|2019-06-04|Apellis Pharmaceuticals, Inc.|Cell-penetrating compstatin analogs and uses thereof|
    FR3006581B1|2013-06-07|2016-07-22|Sofradim Production|PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY|
    FR3006578B1|2013-06-07|2015-05-29|Sofradim Production|PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY|
    EP3000433A1|2014-09-29|2016-03-30|Sofradim Production|Device for introducing a prosthesis for hernia treatment into an incision|
    EP3000432A1|2014-09-29|2016-03-30|Sofradim Production|Textile-based prosthesis for treatment of inguinal hernia|
    EP3029189B1|2014-12-05|2021-08-11|Sofradim Production|Prosthetic porous knit, method of making same and hernia prosthesis|
    AU2016219257B2|2015-02-12|2020-06-25|Neonc Technologies Inc.|Pharmaceutical compositions comprising perillyl alcohol derivatives|
    EP3059255B1|2015-02-17|2020-05-13|Sofradim Production|Method for preparing a chitosan-based matrix comprising a fiber reinforcement member|
    EP3085337A1|2015-04-24|2016-10-26|Sofradim Production|Prosthesis for supporting a breast structure|
    EP3106185B1|2015-06-19|2018-04-25|Sofradim Production|Synthetic prosthesis comprising a knit and a non porous film and method for forming same|
    CA2993661A1|2015-08-04|2017-02-09|Rigel Pharmaceuticals, Inc.|Benzazole compounds and methods for making and using the compounds|
    EP3195830B1|2016-01-25|2020-11-18|Sofradim Production|Prosthesis for hernia repair|
    EP3475263A1|2016-06-27|2019-05-01|Rigel Pharmaceuticals, Inc.|2,4-diamino-pyrimidine compounds and method for making and using the compounds|
    EP3312325B1|2016-10-21|2021-09-22|Sofradim Production|Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained|
    WO2018081294A1|2016-10-26|2018-05-03|Rigel Pharmaceuticals, Inc.|Pyrazole amide compounds as irak inhibitors|
    EP3532470A1|2016-10-26|2019-09-04|Rigel Pharmaceuticals, Inc.|Oxazole derivatives for use as irak inhibitors and method for their preparation|
    CN110691598A|2016-12-29|2020-01-14|赛列尼蒂治疗有限公司|Metalloenzyme inhibitor compounds|
    WO2018125799A2|2016-12-29|2018-07-05|Viamet Pharmaceuticals , Ltd.|Metalloenzyme inhibitor compounds|
    WO2018187530A1|2017-04-06|2018-10-11|Sustain Holdings, Llc|Collagen peptide-based medicament compositions and devices and methods of production and use thereof|
    RU2019131869A3|2017-04-07|2021-07-09|||
    EP3398554A1|2017-05-02|2018-11-07|Sofradim Production|Prosthesis for inguinal hernia repair|
    EP3645525A1|2017-06-29|2020-05-06|Rigel Pharmaceuticals, Inc.|Kinase inhibitors and methods for making and using|
    CA3096078A1|2018-04-06|2019-10-10|The Trustees Of The University Of Pennsylvania|Compstatin analogs with increased solubility and improved pharmacokinetic properties|
    CA3099037A1|2018-05-03|2019-11-07|Rigel Pharmaceuticals, Inc.|Rip1 inhibitory compounds and methods for making and using the same|
    US10975064B2|2018-05-03|2021-04-13|Rigel Pharmaceuticals, Inc.|RIP1 inhibitory compounds and methods for making and using the same|
    WO2020092845A1|2018-11-01|2020-05-07|Rigel Pharmaceuticals, Inc.|Method and composition embodiments for treating acute myeloid leukemia|
    US20200377518A1|2019-05-29|2020-12-03|Rigel Pharmaceuticals, Inc.|Method of preventing and treating thrombosis|
    WO2021026451A1|2019-08-08|2021-02-11|Rigel Pharmaceuticals, Inc.|Compounds and method for treating cytokine release syndrome|
    WO2021030526A1|2019-08-14|2021-02-18|Rigel Pharmaceuticals, Inc.|Method of blocking or ameliorating cytokine release syndrome|
    WO2021041898A1|2019-08-30|2021-03-04|Rigel Pharmaceuticals, Inc.|Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations|
    WO2021046437A1|2019-09-06|2021-03-11|Rigel Pharmaceuticals, Inc.|Rip1 inhibitory compounds and methods for making and using the same|
    US20210070743A1|2019-09-06|2021-03-11|Rigel Pharmaceuticals, Inc.|Rip1 inhibitory compounds and methods for making and using the same|
    US20210139494A1|2019-11-07|2021-05-13|Rigel Pharmaceuticals, Inc.|Heterocyclic rip1 inhibitory compounds|
    法律状态:
    2002-08-22| STCF| Information on status: patent grant|Free format text: PATENTED CASE |
    2002-11-13| AS| Assignment|Owner name: CLN DIAGNOSTICS & THERAPEUTICS, INC., OKLAHOMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COLLAGENESIS, INC.;REEL/FRAME:013475/0608 Effective date: 20020808 |
    2005-09-20| FPAY| Fee payment|Year of fee payment: 4 |
    2010-04-19| REMI| Maintenance fee reminder mailed|
    2010-07-15| SULP| Surcharge for late payment|Year of fee payment: 7 |
    2010-07-15| FPAY| Fee payment|Year of fee payment: 8 |
    2014-02-28| FPAY| Fee payment|Year of fee payment: 12 |
    2014-04-17| AS| Assignment|Owner name: EUCLID SYSTEMS CORPORATION, VIRGINIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CLN DIAGNOSTICS & THERAPEUTICS, INC.;REEL/FRAME:032694/0368 Effective date: 20101115 |
    优先权:
    申请号 | 申请日 | 专利标题
    US09/083,899|US6197934B1|1998-05-22|1998-05-22|Compound delivery using rapidly dissolving collagen film|
    US09/735,182|US6448378B2|1998-05-22|2000-12-12|Compound delivery using rapidly dissolving collagen film|US09/735,182| US6448378B2|1998-05-22|2000-12-12|Compound delivery using rapidly dissolving collagen film|
    [返回顶部]